Multiple blockbuster drugs set to lose exclusivity, producing one of the pharmaceutical industry's most financially significant patent cliffs in over a decade, according to
Oncology is one of the key therapy areas set to be affected by pricing pressures as drug patents expire.
Pharma companies will need to "rethink revenue strategies, pipeline investments, and lifecycle management to safeguard long-term growth", as a greater number of biosimilars and generic medicines gain market entry, according to a recent report by the data and analytics company.
As such, the US market is expected to lose over
Which blockbuster drugs could be impacted in the next pharmaceutical patent cliff?
Major drugs including
However,
"To effectively navigate a patent cliff, companies must deploy a range of strategies… life cycle management and patent thickets can be effective tools to extend market exclusivity and defend against generic competition”
"More than half of the top 15 pharma companies are expected to face challenges in managing the impact of the upcoming patent cliff. However, some companies have pipeline drugs forecast to offset part of these losses," explained
"To effectively navigate a patent cliff, companies must deploy a range of strategies to offset losses and strengthen their long-term position. These may include acquiring early-stage biotechs developing promising therapies and increasing investment in R&D, targeting diseases with high unmet needs. Additionally, life cycle management and patent thickets can be effective tools to extend market exclusivity and defend against generic competition," El-Helou added.
Yet, impact of the pharmaceutical patent cliff on provides a "significant opportunity" for pharma companies, according to
The post Next drug patent cliff to challenge Big Pharma strategy appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2025. All Rights Reserved., source
